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SINCE the original studies of Barnes,
Loutit and Neal (1956), allogeneic lym-
phoid cells from either normal or specifi-
cally immunized donors have been used
in various ways, either alone or in com-
bination with other forms of therapy, to
inhibit tumour growth (Fefer, 1973;
Santos, 1972). Usually allogeneic cells
have been more effective against leukae-
mias or ascites tumours than solid tumours
(Wigzell, 1]961; Woodruff, Symes and
Stuart, 1963) and any inhibitory effect
observed has appeared rather as prolonged
survival than complete suppression of
tumour growth (Katz et al., 1972; Ellman
et al., 1972). In some instances, extensive
destruction of tumour has occurred but
this beneficial effect has been offset by a
high mortality from graft-versus-host
disease (Woodruff and Symes, 1962). We
now describe experiments in which a
non-fatal graft-versus-host reaction fre-
quently produced complete inhibition of
growth of a weakly antigenic strain
specific transplantable squamous car-
cinoma which has been maintained in a
highly inbred subline of Wistar rats
(Baldwin, 1966). Developing from these
studies, additional experiments were
designed to determine the immunothera-
peutic value of this graft-versus-host
effect in preventing recurrence of tumours
after resection of small tumours (about
10 mm in diameter); the preliminary
results ofthese experiments are presented.
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In a previous investigation, this tum-
ourhasbeenshowntobecapable ofgrowing
in Fl hybrids between this subline and
DA (Agouti) rats, but it will not grow
in homozygous DA rats (Rumma and
Davies, 1974). This report presents the
results of two separate studies. In both
studies Fl hybrids were injected sub-
cutaneously on Day 0 in the flank with a
standard dose of 1 x 104 tumour cells
in a suspension previously prepared by
mechanical dissociation of solid tumour
from homozygous parental strain Wistar
rats and stored until required in liquid
nitrogen with 100% dimethylsulphoxide as
cryopreservative. At the same time, in
Study 1 (Table I), the rats received an
intraperitoneal injection of spleen cells
either from Wistar or DA parental strain
rats or from allogeneic (Lewis) rats, in
doses which ranged from 12-5 x 106 to
200 x 106 cells. Control rats received
either tumour and syngeneic Fl hybrid
spleen cells or tumour cells alone. The
rats were then examined twice weekly for
signs of graft-versus-host disease and
tumour growth. When animals died or
were destroyed because of extensive
disabling tumour, a full necropsy was
carried out and the tumour or tumour
inoculation site, lungs, liver and spleen
were examined histologically. Animals
which did not die from tumour or graft-
versus-host disease were observed for
two months after the last death in theSURVIVAL OF Fl HYBRID RATS 135
TABLE l.-The Effects of Intraperitoneal Administration of Parental and Allogeneic
Strain Spleen Cells to Wistar x DA Fl Hybrid Rats Injected Subcutaneously with
104 Transplantable Strain-specific Carcinoma Cells
Tumour
takes
23
4
8
8
8
4
32
4
6
7
7
4
28
4
8
8
8
2
30
4
8
8
8
4
32
Mortality from
Tumotir
23
4
7
8
8
4
31
4
4
21
6
3
193
4
5
21
32
1
153
3
6
6
5
4
245
Tumours
GVHD regressing
0 0
0 0
0 1
0 0
0 0
0 0
0 1
0 0
0 3
0 52
0 1
1 0
1 85
0
2
5
5
3
15
0
0
0
0
0
0
0
4
3
3
0
104
1
2
2
3
0
85
No. of
suirvivors
0
0
1
0
0
I1
0
4
61
2
0
123
0
1
1
0
2
2
2
3
0
I Significantly different from syngeneic cell controls at same dose P<0 01 (Fisher's exact test).
2 Significantly different from syngeneic cell controls at same dose P<0 05 (Fisher's exact test).
3 Totals significantly different from syngeneic cell controls P< 0-001 (X2 test).
4Totals significantly different from syngeneic cell controls P< 005 (x2 test).
Totals significantly different from syngeneic cell controls P<0-025 (x2 test).
TABLE II.-(Comparative Effects of Tumour Excision and Immunotherapy on the
Incidence of Tumour Recurrence
Experimental group'
Untreated controls (Tu. D 0)
Tu. D 0 Surg. D 21
Tu. D 0-GVHR D 14-Surg.
D 21
Tu. D 0---GVHR D 21 Suirg.
D 21
Average tumour
size at, resection
(mm±S.D.)
(8 * 9± 1*1)
9 7± 1* 5
8-5±2 0
10-4+1- 5
No. of %
recurrences "cure(l"
(7/7) 0
7/10 30
3/11 73 NS 76 - 7 ± 30* 7 NS
4/8 50 NS 56 *3±7 * 3 NS
I Tu., Tumour; D, Day; Sturg., Surgery; GVHR, graft-versuis-host reaction.
2 Data compiled on rats developing tumour recurrences.
3 Probability based on Fisher's exact test. NS, Not significantly different from group with surgery alone.
4 Probability base(d on Student's t test. NS, not, significantly different from group with surgery alone.
same experimental group, then they were
killed and their tissues examined histo-
logically for tumour and signs of graft-
versus-host disease. In StuLdy 2 (Table II)
tumours reaching a diameter of about
10 mm were resected on Day 21. In the
case of graft-versus-host immunotherapy,
50 X 106 spleen cells from Wistar parental
strain rats were injected intraperitoneally
either on Day 14 or Day 21 respectively.
Spleen
cell donor
None
FI Hybrid
Wistar
DA
Lexvis
Dose of
spleen
cellsXl1(6
0
12 5
25
50
loo
200
All (loses
12-5
25
50
100
200
All doses
12 5
25
50
100
200
All closes
12-5
25
50
100
200
All doses
No. of
Irats
23
4
8
8
8
4
32
4
8
8
8
4
32
4
8
8
8
4
:32
4
8
8
8
4
:32
Time of death
after excision
(days± S.D.)2
(55-6±9-1)
54-4±5-7J.. RUMMA AND D. J. DAVIES
The effectiveness of the treatment was
measured by the number ofrats surviving
more than 3 months. They are referred
to as "cures" in the results.
In Study 1, the results of several
experiments of the same kind were pooled
and are summarized in Table I. In
control rats, all 23 given tumour alone
and 31 of 32 given tumour and syngenieic
spleen cells died with widespread meta-
stases; in the remaining one animal in
the latter group the tumour grew to a
diameter of 4 mm and then regressed
completely. In those rats injected with
spleen cells from the tumour susceptible
Wistar parental strain there was a marked
reduction of mortality from the tumour,
particularly with doses of 25 x 106 and
50 x 106 cells. In some of these the
tumour failed to take but in others it
grew up to a diameter of 15 mm over a
period of4 weeks before regressing. Hist-
ological examination ofthe tumour inocu-
lation site in these cases showed a small
nodule of dense fibrous tissue containing
necrotic or degenerate tumour cells.
When a dose of lOOx106 and 200X106
Wistar spleen cells wasused, mortality was
higher but this was mainly due to tumour
growth; only one animal given 200X 106
diedfromgraft-versus-host disease. How-
ever, in animals in these groups dying
with tumour the survival time was pro-
longed and, although massive tumours
developed at the site of inoculation, there
was no evidence of the usual secondary
spread to other organs. Tumour regres-
sion was also associated with inoculation
of spleen cells from the tumour resistant
DA parental strain rats with all but the
lowest cell dose but, in contrast with the
Wistar cells, DA cells produced a high
mortality from graft-versus-host disease
so that there were few survivors in this
group. In 2 rats given 25 x 106 DA cells
tumours which grew up to a diameter of
25 mm over 4 weeks regressed, in one
completely, while in the other rat the
tumour regressed to a diameter of 7 mm,
however, only to resume progressive
growth, eventually killing the host.
Regression of tumours also occurred on
occasions with inoculation of allogeneic
Lewis cells at most doses. These cells
were less effective than parental Wistar
strain cells when considering the number
of survivors but they did not induce
graft-versus-host disease so thattherewere
more survivors than in the group given
DA cells.
The preliminary results ofthe immuno-
therapeutic value of a graft-versus-host
reaction in preventing the recurrence of
tumours in surgically resected animals are
summarized in Table II. The most
effective regimen was obtained with appli-
cation of a graft-versus-host reaction on
Day 14, followed by surgery on Day 21.
Inthesameregimen,whenimmunotherapy
was delayed for 7 days the number of
cures decreased. Immunotherapy alone
on Day 14 was unable to cope with estab-
lished tumours(unpublishedobservations).
The results show that injection of
non-syngeneic spleen cells can in a limited
range prevent the growth of a solid trans-
planted malignant tumourwithoutcausing
death from graft-versus-host disease
(Table I). Previous studies have shown
that lymphoid cells of different inbred
strains of rats vary considerably in the
type of graft-versus-host reaction that
they produce (Elkins, 1970) and in the
present study lethal disease occurred
consistently more often with parental
DA cells than with equivalent doses of
Wistar cells of the other parental strain,
although this was not paralleled by any
significantly greater effectiveness in
inhibiting tumour growth. As has been
shown previously with a methylcholan-
threne induced sarcoma (Medzihradsky,
1969; Medzihradsky, Konikova and
Novotna, 1973), increasing the dose of
lymphoid cells beyond a certain level
produces less inhibition oftumour growth
as well as increased mortality from graft-
versus-host disease.
Because the lymphoid cells that were
most effective in producing tumour inhib-
ition are syngeneic with the tumour, this
effect cannot be explained as an allograft
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rejection reaction. We are probably
witnessing an example of the allogeneic
effect in which a variety ofimmunological
and inflammatory responses arestimulated
by foreign lymphoid cells (Elfenbein,
Green and Paul, 1974; Osborne and Katz,
1973); this effect has previously been
shown to inhibit progress of leukaemia
(Katz et al., 1972; Ellman et al., 1972).
The tumour used in the present study
excites a weak host cellular immune res-
ponse which does not obviously affect
growth (Flannery et al., 1973) but injection
of BCG can induce host resistance to this
tumour (Baldwin and Pimm, 1973) and
perhaps the injection of parental or allo-
geneic lymphoid cells gives a similar
augmentation ofhost anti-tumour immune
response. In fact, preliminary results
have shown under in vitro conditions
that, shortly after the induction ofa graft-
versus-host reaction, spleen cells from
tumour bearing Fl hybrids exert a sig-
nificantly stronger cytotoxic effect upon
tumour target cells of the tumour sus-
ceptible Wistar parental strain than
spleen cells from animals given tumour
alone (Rumma, in preparation). Further-
more, the possibility that the cancerous
hosts were being stimulated to cope with
metastases when a touch of graft-versus-
host reaction was used in combinationwith
surgical excision was indicated by the
marked increase in cures obtained with
this combination of therapies than when
surgery alone was used. However, the
fact that no significant prolongation of
survival oftheremaining ratswasobtained
in the combined therapy would indicate
that survival might well have been dep-
endent upon a critical ratio of metastases
to immune responsestatus. Nevertheless,
the preliminary results strongly suggest
that a controlled graft-versus-host reaction
might become an effective anti-tumour
adjunct in controlling residual tumour
remaining after excision ofthe main mass.
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